Kellie Schmitt

Phase Genomics CEO Ivan Liachko shifts company to R&D focus after pandemic hits revenue; one furlough, no layoffs

Phase Genomics, a five-year-old University of Washington spinoff led by CEO Ivan Liachko, shifted to skeleton lab crews and remote work during the pandemic, cutting revenue and furloughing one employee while focusing R&D inward to adapt and continue innovating. The company is adjusting its genomics technology amid Seattle's biotech disruption and exploring ways to help with COVID-19 research.